Results

1–10 of 168 results for Retinal Vascular Disease

Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025
Efficacy and Safety Outcomes Over 12 Weeks With OCS-01 Eye Drops in DME From DIAMOND-Stage 1 Trial:Focus on Subgroup by Prior Treatment Status
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2025
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025
Population Pharmacokinetics and Safety of OPT-302 an Anti-VEGF-C--D Trap in Patients With Retinal Vascular Diseases
Dante Joseph Pieramici, MD
Annual Meeting Talks
2023
Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2
Emily Y. Chew, MD
Annual Meeting Talks
2023
Intraoperative Fluorescein Angiography to Efficiently Identify Many Biomarkers and Guide Surgical Decision-Making
Alan J. Franklin, MD, PhD
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Reducing Time to Treatment of Retinal Artery Occlusions Using a Remote Diagnostic Protocol
Gareth Lema, MD, PhD
Annual Meeting Talks
2024
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024